Table 2. Clinical characteristics of patients with chronic kidney disease (CKD) and early gastric cancer (EGC).
| Total | Stage 3 | Stage 4 | Stage 5 | P-value | |
| Number, n | 144 | 92 | 23 | 29 | – |
| Age | 73.8 ± 7.9 | 73.6 ± 7.5 | 73.8 ± 10.1 | 74.9 ± 7.6 | 0.592 |
| Sex, male (%) | 113 (78.5) | 75 (81.5) | 15 (65.2) | 23 (79.3) | 0.228 |
| Body height, cm | 160.3 ± 9.5 | 161.6 ± 9.1 | 157.0 ± 9.3 | 159.4 ± 10.8 | 0.063 |
| Body weight, kg | 59.0 ± 12.5 | 60.5 ± 12.8 | 58.3 ± 12.5 | 56.2 ± 10.6 | 0.248 |
| eGFR, mL/min | 36.4 ± 18.3 | 48.7 ± 7.7 | 23.6 ± 7.1 | 7.5 ± 2.3 | < 0.001 |
| Cr, mg/dL | 2.51 ± 2.84 | 1.12 ± 0.21 | 2.18 ± 1.26 | 7.23 ± 3.14 | < 0.001 |
| Hb, g/dL | 12.0 ± 1.9 | 12.8 ± 1.7 | 10.7 ± 1.5 | 10.4 ± 1.4 | < 0.001 |
| PLT, 104/µL | 19.5 ± 5.8 | 19.7 ± 5.5 | 19.9 ± 6.0 | 18.8 ± 7.3 | 0.453 |
| Hemodialysis, n (%) | 19 (13.2) | 0 (0) | 0 (0) | 19 (65.5) | < 0.001 |
| Diabetes mellitus, n (%) | 40 (27.8) | 17 (18.5) | 7 (30.4) | 16 (55.2) | < 0.001 |
| Antithrombogenic agents, n (%) | 43 (29.9) | 19 (20.7) | 9 (39.1) | 15 (51.7) | 0.004 |
| Heparin replacement therapy, n (%) | 7 (4.9) | 4 (4.3) | 2 (8.7) | 1 (3.4) | 0.638 |
eGFR, estimated glomerular filtration rate; PLT, platelet count.Stages from Kidney Disease Improving Global Outcomes Guidelines: stage 3, eGFR: 30 – 59 mL/min; stage 4, eGFR: 15 – 29 mL/min; stage 5, eGFR: < 15 mL/min.